✦ LIBER ✦

Immune therapy for chronic inflammatory demyelinating polyneuropathy: from clinical trials to real-life

✍ Scribed by Y. A. Rajabally

Book ID: 111066135
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 67 KB
Volume: 17
Category: Article
ISSN: 1351-5101
DOI: 10.1111/j.1468-1331.2009.02804.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improvement of quality of life in patien

Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20

✍ Cocito, Dario; Paolasso, Ilaria; Peci, Erdita; Spagone, Emanuela; Lopiano, Leona 📂 Article 📅 2013 🏛 Springer Milan 🌐 English ⚖ 128 KB

Spreading of autoimmunity from central t

Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy

✍ M. Falcone; A. Scalise; C. Minisci; D. Romito; I. Cancelli; G. L. Gigli 📂 Article 📅 2006 🏛 Springer Milan 🌐 English ⚖ 202 KB

First-line treatment of chronic hepatiti

First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice

✍ S. Pol; P. Lampertico 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views

FCET2EC (From controlled experimental tr

FCET2EC (From controlled experimental trial to = 2 everyday communication): How effective is intensive integrative therapy for stroke-induced chronic aphasia under routine clinical conditions? A study protocol for a randomized controlled trial

✍ Baumgaertner, Annette; Grewe, Tanja; Ziegler, Wolfram; Floel, Agnes; Springer, L 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 506 KB

Dasatinib, even at low doses, is an effe

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

✍ Giuseppe Visani; Massimo Breccia; Antonella Gozzini; Giorgina Specchia; Enrico M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 640 KB